⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARQT News
Arcutis Biotherapeutics, Inc. Common Stock
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
globenewswire.com
ARQT
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results
globenewswire.com
ARQT
Arcutis to Present at Upcoming Investor Conferences
globenewswire.com
ARQT
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
globenewswire.com
ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
globenewswire.com
ARQT
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ARQT
Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025
globenewswire.com
ARQT